SK285284B6 - Vodný prostriedok umožňujúci stabilizáciu PEG-interferón alfa konjugátov, spôsob výroby lyofilizovaného prášku a výrobok s jeho obsahom - Google Patents

Vodný prostriedok umožňujúci stabilizáciu PEG-interferón alfa konjugátov, spôsob výroby lyofilizovaného prášku a výrobok s jeho obsahom Download PDF

Info

Publication number
SK285284B6
SK285284B6 SK1426-2000A SK14262000A SK285284B6 SK 285284 B6 SK285284 B6 SK 285284B6 SK 14262000 A SK14262000 A SK 14262000A SK 285284 B6 SK285284 B6 SK 285284B6
Authority
SK
Slovakia
Prior art keywords
interferon alpha
peg
aqueous composition
water
conjugates
Prior art date
Application number
SK1426-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK14262000A3 (sk
Inventor
Douglas F. Kline
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21957085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK285284(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of SK14262000A3 publication Critical patent/SK14262000A3/sk
Publication of SK285284B6 publication Critical patent/SK285284B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SK1426-2000A 1998-03-26 1999-03-24 Vodný prostriedok umožňujúci stabilizáciu PEG-interferón alfa konjugátov, spôsob výroby lyofilizovaného prášku a výrobok s jeho obsahom SK285284B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4890798A 1998-03-26 1998-03-26
PCT/US1999/004268 WO1999048535A1 (en) 1998-03-26 1999-03-24 Formulations for protection of peg-interferon alpha conjugates

Publications (2)

Publication Number Publication Date
SK14262000A3 SK14262000A3 (sk) 2001-04-09
SK285284B6 true SK285284B6 (sk) 2006-10-05

Family

ID=21957085

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1426-2000A SK285284B6 (sk) 1998-03-26 1999-03-24 Vodný prostriedok umožňujúci stabilizáciu PEG-interferón alfa konjugátov, spôsob výroby lyofilizovaného prášku a výrobok s jeho obsahom

Country Status (26)

Country Link
EP (1) EP1066059B1 (no)
JP (3) JP3643034B2 (no)
KR (1) KR100420642B1 (no)
CN (1) CN1191863C (no)
AR (1) AR014772A1 (no)
AT (1) ATE297761T1 (no)
AU (1) AU754002B2 (no)
BR (1) BR9909087A (no)
CA (1) CA2324467C (no)
CO (1) CO5080738A1 (no)
CZ (1) CZ302005B6 (no)
DE (1) DE69925820T2 (no)
ES (1) ES2241272T3 (no)
HK (1) HK1029754A1 (no)
HU (1) HU228877B1 (no)
ID (1) ID28470A (no)
IL (2) IL138221A0 (no)
MY (1) MY119227A (no)
NO (1) NO329916B1 (no)
NZ (1) NZ506631A (no)
PE (1) PE20000338A1 (no)
PL (1) PL193286B1 (no)
PT (1) PT1066059E (no)
SK (1) SK285284B6 (no)
TW (2) TWI243057B (no)
WO (1) WO1999048535A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID28470A (id) * 1998-03-26 2001-05-24 Schering Corp Formulasi-formulasi untuk perlindungan terhadap konjugasi polietilen glikol-interferon alfa
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
ES2319777T3 (es) * 1999-04-08 2009-05-12 Schering Corporation Tratamiento de carcinoma de celulas renales.
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
WO2001052882A1 (en) * 2000-01-24 2001-07-26 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
KR100353392B1 (ko) * 2000-03-13 2002-09-18 선바이오(주) 높은 생체 활성도를 갖는 생체 활성 단백질과 peg의결합체 제조방법
CA2404737C (en) 2000-04-03 2010-06-29 Santen Pharmaceutical Co., Ltd. Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug
DE60321450D1 (de) 2002-02-22 2008-07-17 Schering Corp Pharmazeutische zubereitungen von antineoplastischen wirkstoffen, insbesondere temozolomid, verfahren zu ihrer herstellung und deren verwendung
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
US7632491B2 (en) * 2004-08-12 2009-12-15 Schering Corporation Stable pegylated interferon formulation
PT2234645E (pt) 2007-12-20 2012-05-21 Merck Serono Sa Formulações de peg-interferão-beta
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
KR20150074167A (ko) * 2012-10-26 2015-07-01 루핀 리미티드 Peg 인터페론 알파-2b의 안정한 약학 조성물
KR101736870B1 (ko) 2014-08-20 2017-05-18 한국코러스 주식회사 인터페론 접합체를 포함하는 복합체 및 이의 제조방법
HUE057856T2 (hu) 2016-06-01 2022-06-28 Servier Ip Uk Ltd Polialkilén-oxid-aszparagináz készítményei és eljárás ezek elõállítására és alkalmazására
CN112358541B (zh) * 2020-11-25 2022-04-01 广州迪澳医疗科技有限公司 一种重组人γ-干扰素的冻干保护剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2024046A1 (en) * 1989-09-28 1991-03-29 Alberto Ferro Stabilized leukocyte-interferons
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
EP0730470B1 (en) * 1993-11-10 2002-03-27 Enzon, Inc. Improved interferon polymer conjugates
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
SI2275119T1 (sl) * 1995-07-27 2013-12-31 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
AU7473096A (en) * 1995-11-02 1997-05-22 Schering Corporation Continuous low-dose cytokine infusion therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
ID28470A (id) * 1998-03-26 2001-05-24 Schering Corp Formulasi-formulasi untuk perlindungan terhadap konjugasi polietilen glikol-interferon alfa

Also Published As

Publication number Publication date
CZ20003315A3 (cs) 2001-04-11
TW200536557A (en) 2005-11-16
PL345568A1 (en) 2001-12-17
TWI243057B (en) 2005-11-11
CA2324467C (en) 2002-11-05
AU3181299A (en) 1999-10-18
WO1999048535A1 (en) 1999-09-30
JP2003221345A (ja) 2003-08-05
CZ302005B6 (cs) 2010-09-01
JP2002507583A (ja) 2002-03-12
CO5080738A1 (es) 2001-09-25
CA2324467A1 (en) 1999-09-30
ATE297761T1 (de) 2005-07-15
NO20004785D0 (no) 2000-09-25
AU754002B2 (en) 2002-10-31
IL138221A0 (en) 2001-10-31
EP1066059B1 (en) 2005-06-15
KR100420642B1 (ko) 2004-03-02
JP4580744B2 (ja) 2010-11-17
JP2005104985A (ja) 2005-04-21
EP1066059A1 (en) 2001-01-10
PL193286B1 (pl) 2007-01-31
NO20004785L (no) 2000-09-25
NO329916B1 (no) 2011-01-24
CN1191863C (zh) 2005-03-09
JP3643034B2 (ja) 2005-04-27
DE69925820D1 (de) 2005-07-21
CN1295484A (zh) 2001-05-16
DE69925820T2 (de) 2006-05-18
TWI250024B (en) 2006-03-01
HUP0101749A3 (en) 2001-12-28
SK14262000A3 (sk) 2001-04-09
PT1066059E (pt) 2005-10-31
KR20010034654A (ko) 2001-04-25
NZ506631A (en) 2003-03-28
AR014772A1 (es) 2001-03-28
HU228877B1 (en) 2013-06-28
PE20000338A1 (es) 2000-05-16
IL138221A (en) 2007-12-03
ID28470A (id) 2001-05-24
HUP0101749A2 (hu) 2001-11-28
HK1029754A1 (en) 2001-04-12
BR9909087A (pt) 2000-12-05
ES2241272T3 (es) 2005-10-16
MY119227A (en) 2005-04-30

Similar Documents

Publication Publication Date Title
US6180096B1 (en) Formulations for protection of peg-interferon alpha conjugates
SK285284B6 (sk) Vodný prostriedok umožňujúci stabilizáciu PEG-interferón alfa konjugátov, spôsob výroby lyofilizovaného prášku a výrobok s jeho obsahom
JP4971160B2 (ja) 安定するpeg化インターフェロン処方物
KR20070046791A (ko) 안정성이 증가된 생체분자-함유 제형
JP5138699B2 (ja) Peg−インターフェロンアルファ接合体の配合物
JP5179521B2 (ja) ペグ‐インターフェロンアルファ接合体および凍結保護剤としてラフィノースを含む組成物
KR20150074167A (ko) Peg 인터페론 알파-2b의 안정한 약학 조성물
KR20180114018A (ko) 동결 건조된 약학적 제제 및 그의 용도
MXPA00007209A (en) Formulations for protection of peg-interferon alpha conjugates

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, NJ, US

Effective date: 20121108

MK4A Expiry of patent

Expiry date: 20190324